Clinical trials: Tobacco Smoking
Smoking, Tobacco Use Disorder
A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers
A randomized, double-blind, active-controlled, crossover, pilot study to evaluate the safety and efficacy of CigRx™ Lozenge, a dietary supplement, in daily smokers in temporarily reducing the desire to smoke
- Trial name
- NCT01262170
- Testing
- CigRx Lozenge, Tobacco Lozenge
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Rock Creek Pharmaceuticals, Inc.
Smoking, Abdominal Aortic Aneurysm
Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.
The purpose of this study was to evaluate the reduction of the Abdominal Aortic Aneurysm (AAA) annual growth rate in patients who switched from smoking cigarettes to using IQOS as compared to patients who continued to smoke…
- Conditions
- Smoking, Abdominal Aortic Aneurysm, IQOS Use
- Trial name
- NCT03837704
- Testing
- IQOS, Cigarette, Smoking Cessation
- Where
- 13 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Philip Morris Products S.A.
Pulmonary Disease, Chronic Obstructive
Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.
Post marketing Surveillance to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) on health-related quality of life in COPD patients who stopped smoking during treatment and to obtain safety data…
- Trial name
- NCT02172547
- Testing
- Spiriva
- Volunteers
- 10,821 people
- Sponsor
- Boehringer Ingelheim
Smoking, Smoking Behaviors
Abuse Liability for Four Heated Tobacco Product (HTP) Consumables and Two HTP Devices
This is a single-site, open-label, randomized, 8-way crossover study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics [PD]) and plasma nicotine…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT07267195
- Testing
- Product A, Product N, Product B
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking
A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)
The purpose of this study is to evaluate the safety and tolerability of an investigational drug that may help individuals to stop smoking.
- Trial name
- NCT00109135
- Testing
- taranabant
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Postmenopause
To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets .
A Drug-Drug Interaction Study to Evaluate the Effect of Smoking (CYP1A2 Inducer) on the Pharmacokinetics Following a Single Oral Dose of GS1-144 Tablets in Chinese Healthy Postmenopausal Female Trial Participants
- Trial name
- NCT07534176
- Testing
- GS1-144 tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Smoking Cessation, Pharmacokinetics
A Clinical Trial to Compare Pharmacokinetics of the "CDFF0318" and "Champix Tab. 1mg"
A Phase 1 Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics after Administration of the "CDFF0318" and "Champix Tab. 1mg (Varenicline tartrate)" in Healthy Male Volunteers
- Trial name
- NCT04631874
- Testing
- CDFF0318, Champix
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- CTC Bio, Inc.
Smoking, Tobacco Use
CSD190301: A Study to Assess Elements of Abuse Liability for Two Dissolvable Nicotine Lozenge Tobacco Products
This is a two-arm, single use, single-center, randomized, 10-sequence per arm, open-label, crossover pharmacokinetic/pharmacodynamic (PK/PD) study, designed to evaluate elements of abuse liability (AL) including subjective…
- Conditions
- Smoking, Tobacco Use, Tobacco Smoking
- Trial name
- NCT04167384
- Testing
- Product A, Product B, Product C
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking Cessation
Cumulative Skin Irritation Potential of a New 15 mg Nicotine Patch
An investigation on the cumulative skin irritation potential of a newly developed 15 mg nicotine patch. Evaluation of skin irritation of a newly developed 15 mg nicotine transdermal patch.
- Trial name
- NCT00965913
- Testing
- Nicotine Patch, Nicotine Patch Comparator
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- McNeil AB
Smoking Cessation
12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation.
- Trial name
- NCT00150254
- Testing
- CP-526,555 (varenicline)
- Where
- 13 sites in United States
- Volunteers
- 625 people
- Sponsor
- Pfizer
Tobacco Use
A Mobile App Based Cognitive Dissonance Intervention for Smoking Cessation
This research study aims to develop a cognitive dissonance-based mobile app for smoking cessation (Support2Quit) and test the efficacy of the app with 500 adult smokers who express a desire to quit smoking.
- Trial name
- Support2Quit (NCT05797155)
- Testing
- Support2Quit App - Cognitive Dissonance Based Smoking Cessation + Smoking Cessation Tips, Tips for Smoking Cessation App
- Where
- United States
- Volunteers
- 437 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Healthy Volunteers
The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking
This will be a phase 1 randomized, double-blind, 2-period, 2-sequence crossover trial enrolling 6 healthy volunteers to assess the impact of IV-administered Bendavia on the endothelial dysfunction induced by a single cigarette.
- Trial name
- NCT01518985
- Testing
- Bendavia, Sterile saline (0.9%), Cigarette smoking
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Mighty Therapeutics, Inc.
Smokers
Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.
This study is designed to determine the efficacy of high nicotine-specific antibody titers in smoking cessation.
- Trial name
- NCT00736047
- Testing
- NIC002
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Novartis
Obesity, Smoking
Africa and Middle East Cardiovascular Epidemiological Study
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics…
- Conditions
- Obesity, Smoking, Dyslipidemia, Diabetes Mellitus
- Trial name
- ACE (NCT01243138)
- Where
- 73 sites in Algeria, Cameroon and 12 more
- Volunteers
- 4,386 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy
Metformin ER 750 mg Tablets, Fed
The objective of this study is to compare the rate and extent of absorption of metformin from a test formulation of Metformin ER 750 mg Tablets versus the reference Glucophage® XR 750 mg Tablets under fed conditions.
- Trial name
- NCT00834613
- Testing
- Glucophage® XR 750 mg Tablets, Metformin ER 750 mg Tablets
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Smoking Cessation, Vaping Cessation
Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers
Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the United States.
- Trial name
- ORCA-OL (NCT06435221)
- Testing
- Cytisinicline
- Where
- 29 sites in United States
- Volunteers
- 479 people
- Sponsor
- Achieve Life Sciences
Smoking, Tobacco Use
BAT3221032: A Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects
This is a randomized, controlled, multi-center, open-label, 8-cohort parallel group study to assess changes in select biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH) in generally healthy smokers switching to…
- Conditions
- Smoking, Tobacco Use, Tobacco Smoking
- Trial name
- NCT05142436
- Testing
- Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B, Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B, Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B
- Where
- 18 sites in United States
- Volunteers
- 806 people, healthy volunteers welcome
- Sponsor
- British American Tobacco (Investments) Limited
Healthy Volunteers
Safety and Pharmacokinetics of Smoked Cannabis in Healthy Patients
No actual human data for pharmacokinetics, metabolism, safety, pharmacodynamics, nor efficacy parameters are available for inhaled medical cannabis.
- Trial name
- NCT04314804
- Testing
- PPP001
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tetra Bio-Pharma
Vaping, E-Cig Use
A Study of Cytisinicline for Vaping Cessation in Adult Smokers
This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the efficacy and safety profile of 3 mg cytisinicline administered TID for 12 weeks for vaping cessation.
- Trial name
- ORCA-V1 (NCT05431387)
- Testing
- cytisinicline, Behavioral support
- Where
- 5 sites in United States
- Volunteers
- 160 people
- Sponsor
- Achieve Life Sciences
Healthy Volunteers
AZD4635 Relative Bioavailability Study
To investigate the pharmacokinetics and relative bioavailability of AZD4635 solid oral formulation and compare with the nano-suspension reference formulation with the option to assess food effect, pH effect and absolute…
- Trial name
- Rel Bio (NCT03710434)
- Testing
- AZD4635 50 mg nano-suspension (reference), AZD4635 solid oral formulation - fasted, AZD4635 solid oral formulation - fed
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- AstraZeneca